High-Quality Immune Checkpoint Antibodies to Detect Immune Regulators
Surgery, chemotherapy, and radiation have been the leading treatments for cancer over the past 100 years. A new form of treatment called immunotherapy has entered the scene and is now at the forefront of oncology research.
Cancer immunotherapy is a method of utilizing the patient’s own immune system to fight cancer. Normally, the immune system utilizes T cell activation to distinguish normal body cells from cancerous, infected, or foreign cells. T cell activation requires fine-tuning of checkpoints that allow healthy cells to be overlooked by the immune system, while unhealthy or aberrant cells are recognized and eliminated.
Many cancer cells have developed mechanisms that allow them to avoid detection by the immune system and grow unchecked. For example, some cancers express surface ligands, such as PD-L1, that bind to receptors on T cells to inhibit their activation, allowing them to evade detection by the immune system.
The goal of immunotherapy is to identify the mechanisms that allow cancer to go undetected and develop compounds that will ignite an immune response specific to the cancer cells.
One of the key areas within this field is a new class of drugs called immune checkpoint inhibitors, which block the action of proteins that act as checkpoints and allow cancer cells to hide from the immune system and survive.
Yervoy® (ipilimumab) is a CTLA-4 blocking antibody, and the first immunotherapy drug. Newer monoclonal antibodies, Keytruda® (pembrolizumab) and Opdivo® (nivolumab) target the immune regulation checkpoint protein PD-1.
Many other immunotherapies targeting immune checkpoint regulators are currently under study and are some of the most promising ongoing developments in cancer treatment.
Immune Checkpoint Antibodies
|Product Name||Catalog #||Applications||Species Reactivity|
|B7-H3 Antibody||CA001||WB, IHC, FC||Human, Mouse, Rat|
|BTLA Antibody||CA002||WB||Mouse, Rat|
|CD27 Antibody||CA003||WB, IHC, IF||Human, Mouse, Rat|
|CD40 Antibody||CA004||WB, IHC||Human, Mouse, Rat|
|CTLA-4 Antibody||CA005||WB||Human, Mouse|
|HVEM Antibody||CA006||WB, IHC||Human|
|ICOS Antibody||CA007||WB, IHC, IF||Human, Mouse, Rat|
|OX40 Antibody||CA009||WB, IHC||Human, Mouse, Rat|
|PD-1 Antibody||CA010||WB, IHC, FC||Human|
|PD-L1 Antibody||CA011||WB, IHC||Human|
|TIM-3 Antibody||CA012||WB||Human, Mouse|
CrownBio is developing numerous research antibodies for detection of immune regulators, which play a role in activating or inhibiting T cell stimulation. Contact us today for more detailed information